Epidemiology and Disease Burden

Atopic dermatitis (AD) is the most common inflammatory skin disease globally, affecting 15-20% of children and 1-3% of adults. Prevalence has tripled since the 1970s, particularly in developed nations. AD causes substantial morbidity: 60% of patients with moderate-severe disease experience sleep disruption; 30% report moderate-to-severe impact on quality of life. Annual healthcare costs exceed $5.3 billion in the United States.

Pathophysiology of Atopic Dermatitis

AD results from complex interaction between genetic predisposition, skin barrier dysfunction, and immune dysregulation. Genetic factors: Loss-of-function mutations in the filaggrin gene (FLG) occur in 10-15% of AD patients. Filaggrin is essential for stratum corneum formation; reduced expression impairs barrier integrity. Barrier dysfunction: Reduced ceramide content (25-50% reduction), abnormal lipid architecture, and elevated transepidermal water loss (TEWL) characterize AD skin.

Immune dysregulation: Type 2 immune activation predominates (Th2, Th22 cells produce IL-4, IL-13, IL-31). IL-4 and IL-13 signaling through the IL-4 receptor promotes IgE production (50-80% of AD patients are atopic with elevated serum IgE), triggers B cell differentiation, and suppresses filaggrin expression. IL-31 from cutaneous lymphocytes directly activates itch receptors on sensory nerves, explaining intense pruritus characteristic of AD.

Clinical Presentation and Diagnosis

AD presents with intense pruritus (itch-scratch cycle is cardinal feature), xerosis (excessive dryness), and acute/chronic inflammation with variable morphology. Acute lesions are erythematous, edematous, vesicular, and oozing. Chronic lesions show lichenification (thickened, cross-hatched skin) from repeated scratching. Distribution varies by age: infants and young children show facial and extensor involvement; older children and adults show flexural distribution (antecubital and popliteal fossae, neck, hands).

Diagnosis uses the Hanifin and Rajka criteria or UK diagnostic criteria. Essential features include early onset, intense pruritus, and chronic relapsing course. Supporting features include atopic personal/family history (asthma, allergic rhinitis, food allergy), elevated serum IgE, and positive skin prick tests. Diagnosis is clinical; no specific diagnostic test exists.

AD Severity Assessment

Severity classification guides treatment intensity: Mild: Limited lesions affecting <10% body surface area (BSA), minimal impact on quality of life. Moderate: 10-50% BSA involvement or significant functional impairment despite localized disease. Severe: >50% BSA involvement or severe impact on sleep and daily activities despite maximal topical therapy. The EASI (Eczema Area and Severity Index) and IGA (Investigator's Global Assessment) quantify disease severity objectively.

First-Line Therapy: Emollients and Barrier Repair

Ceramide-Based Moisturizers: The cornerstone of AD management is liberal use of ceramide-containing emollients (creams and ointments preferred over lotions). Products containing ceramide 1, 3, and 6-II in optimal ratios (CeraVe, Aveeno Eczema Therapy, Eucerin Advanced Cleansing) restore skin barrier integrity. Patients should apply emollients twice daily within 3 minutes of bathing to occlude moisture. Studies show ceramide-based products reduce corticosteroid requirement by 30-50%.

Bathing Modifications: Lukewarm (not hot) water for 5-10 minutes daily followed by immediate emollient application is optimal. Avoid excessive cleansing; gentle, fragrance-free cleansers are preferable. Frequent baths remove natural oils despite subsequent moisturizing, so 2-3 times weekly is reasonable for severe disease.

Topical Corticosteroids

Potency Classes and Dosing: Topical corticosteroids (TCS) are first-line anti-inflammatory therapy. Low-potency agents (hydrocortisone 1%, desonide 0.05%) treat face and intertriginous areas. Mid-potency agents (triamcinolone 0.1%, fluticasone propionate 0.005%) treat trunk and extremities in children; high-potency agents (clobetasol propionate 0.05%) are reserved for adults with severe disease limited to non-facial areas.

Application and Efficacy: Apply TCS to active inflammation twice daily; taper when disease improves. Fingertip unit dosing (0.5g covers approximately 2 hand areas) ensures appropriate quantity. Approximately 70% of mild-moderate AD improves with optimized TCS and emollients alone.

Safety Considerations: Long-term TCS use carries risk of skin atrophy (1-2% with mid-potency, higher with superpotent agents). Monitor for systemic absorption in young children or with large surface area application (>20% BSA). Intermittent TCS (weekends only) can maintain remission in some patients.

Topical Calcineurin Inhibitors

Tacrolimus (0.03% and 0.1% ointment) and pimecrolimus (1% cream) are non-steroidal immunosuppressants that inhibit T cell activation. They are particularly useful for: face and intertriginous areas (avoiding TCS-induced atrophy), patients concerned about steroid side effects, and those requiring long-term control. Tacrolimus 0.1% is comparable to mid-potency TCS in efficacy; clinical response requires 3-4 weeks. A black box warning (2006) regarding theoretical lymphoma risk has not been validated in clinical practice; >20 years of post-marketing data support safety.

PDE4 Inhibitors

Crisaborole (ointment 2%) is a phosphodiesterase-4 (PDE4) inhibitor that reduces inflammatory cytokine production. It is effective for mild-moderate AD and is FDA-approved for ages 2 and older. Crisaborole lacks steroid and calcineurin inhibitor side effects but is generally less potent than mid-potency TCS. Burning sensation during application occurs in 15-25% of patients, limiting palatability.

Systemic Biologic Therapy

Dupilumab (Dupixent): A monoclonal antibody targeting IL-4 receptor alpha (blocking both IL-4 and IL-13 signaling). Dupilumab 300mg subcutaneously every 2 weeks (after 600mg loading dose) produces 40-50% improvement in EASI in 70-75% of moderate-severe AD patients by week 16. Approximately 35% achieve complete/near-complete clearance. FDA-approved for ages 6 months and older.

Tralokinumab (Adtralza): An IL-13-specific monoclonal antibody given as 600mg loading dose, then 300mg every 2 weeks. Clinical trials show EASI-75 response (75% improvement) in 45-50% of patients; efficacy is slightly lower than dupilumab but represents a valuable alternative.

Baricitinib (JAK1/JAK2 inhibitor): A small molecule JAK inhibitor (2mg daily) FDA-approved for moderate-severe AD in adults. Approximately 65% of patients achieve EASI-75 response. Requires monitoring for infections, lipid elevation, and creatinine elevation.

Biologics Selection: Dupilumab is typically first-line for patients with baseline elevated serum IgE or eosinophilia (>400 cells/mcL). Tralokinumab is preferred if IL-4 elevation is suspected. Baricitinib provides rapid onset (3-4 weeks) compared to biologics (8-12 weeks). Switching between biologics is reasonable if inadequate response at 16-20 weeks.

Phototherapy

Narrow-band UVB (NB-UVB) phototherapy (311nm wavelength, 2-3 times weekly) is effective for generalized AD (>10% BSA). Response rates are 60-70% with improvement visible at 8-12 weeks. Phototherapy is particularly valuable during pregnancy when systemic therapies are limited. PUVA (psoralen + UVA) is less safe in children due to carcinogenicity risk.

Managing Acute Flares and Infection

Acute flares are managed with short courses of higher-potency TCS or systemic corticosteroids (0.5-1mg/kg/day prednisone for 1-2 weeks) when infection is excluded. Secondary bacterial colonization (commonly Staphylococcus aureus) is present in 90% of moderate-severe AD. Clinical signs of infection (purulent drainage, honey-crusted lesions) warrant topical or systemic antibiotics (cephalexin 25-50mg/kg/day or doxycycline 100mg twice daily) combined with anti-inflammatory therapy.

Itch Management and Sleep

Pruritus drives disease progression through the itch-scratch cycle. Crotamiton (10% cream), menthol-based preparations, and topical anesthetics provide symptomatic relief. Oral antihistamines offer minimal benefit for AD-associated itch (unlike allergic itch); sedating antihistamines (hydroxyzine 0.5-1mg/kg at bedtime) may improve sleep disruption. Mental health support and cognitive behavioral therapy reduce scratch behaviors in 30-40% of patients.

Monitoring and Follow-Up

Patients on biologics require baseline and periodic laboratory assessment (CBC, liver function tests). Dupilumab requires ophthalmologic evaluation due to rare conjunctivitis (1-2%). Patients should be reassessed at 2-4 weeks after initiating or changing therapy, with goal of achieving clear/nearly clear skin with maintained barrier function.

References

  1. Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;71(1):116-132.
  2. Leung DYM, Soter NA. Cellular and immunological mechanisms in atopic dermatitis. J Am Acad Dermatol. 2001;44(1 Suppl):S1-S12.
  3. Boguniewicz M, Leung DYM. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233-246.
  4. Simpson EL, et al. Dupilumab therapy improves high-need patients with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80(5):1451-1459.
  5. de Bruin-Weller M, et al. Long-term safety and efficacy of tralokinumab in moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2021;147(4):1354-1365.
  6. Theis M, et al. Epidemiology and natural history of atopic dermatitis. Allergy. 2018;73(5):1063-1079.
  7. Guttman-Yassky E, et al. Atopic dermatitis. Nat Rev Dis Primers. 2022;8(1):13.